MX2017013390A - Método para el tratamiento de cáncer pulmonar. - Google Patents
Método para el tratamiento de cáncer pulmonar.Info
- Publication number
- MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A
- Authority
- MX
- Mexico
- Prior art keywords
- fra
- patient
- expression level
- lung cancer
- methods
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 4
- 201000005202 lung cancer Diseases 0.000 title abstract 4
- 208000020816 lung neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 102000010451 Folate receptor alpha Human genes 0.000 abstract 10
- 108050001931 Folate receptor alpha Proteins 0.000 abstract 10
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
se proporcionan en el presente documento métodos para predecir una probabilidad de respuesta al tratamiento con un agente de direccionamiento del receptor alfa de folato (FRA) en un paciente que tiene un cáncer de pulmón que expresa FRA; también se proporcionan métodos para tratar un cáncer de pulmón que expresa FRA en un paciente con un agente de direccionamiento de FRA; los métodos implican cuantificar o determinar el nivel de expresión de FRA del paciente en una muestra biológica y comparar el nivel de expresión de FRA del paciente con un estándar de referencia utilizado para cuantificar el nivel de expresión de FRA, en donde es probable que el paciente responda al tratamiento con el agente de direccionamiento de FRA si el nivel de expresión de FRA del paciente es igual o superior al nivel de expresión de FRA de referencia; también se proporcionan kits relacionados para la predicción de la respuesta y el tratamiento de la población identificada de pacientes con cáncer de pulmón que expresa FRA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149184P | 2015-04-17 | 2015-04-17 | |
| PCT/US2016/027497 WO2016168440A1 (en) | 2015-04-17 | 2016-04-14 | Methods for treating lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013390A true MX2017013390A (es) | 2018-06-13 |
Family
ID=55809240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013390A MX2017013390A (es) | 2015-04-17 | 2016-04-14 | Método para el tratamiento de cáncer pulmonar. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180125970A1 (es) |
| EP (1) | EP3283886B1 (es) |
| JP (1) | JP2018516244A (es) |
| KR (1) | KR20170137848A (es) |
| CN (1) | CN107624071A (es) |
| AU (1) | AU2016248222A1 (es) |
| BR (1) | BR112017022320A2 (es) |
| CA (1) | CA2983126A1 (es) |
| IL (1) | IL255079A0 (es) |
| MX (1) | MX2017013390A (es) |
| RU (1) | RU2718780C9 (es) |
| SG (1) | SG11201708546UA (es) |
| WO (1) | WO2016168440A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006241099B2 (en) * | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| JPWO2015186823A1 (ja) * | 2014-06-06 | 2017-04-20 | 協和発酵キリン株式会社 | Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬 |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| CN115925952A (zh) | 2018-03-13 | 2023-04-07 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| WO2019243900A2 (en) * | 2018-06-18 | 2019-12-26 | Mosaic Biomedicals Slu | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| CN110221052B (zh) * | 2019-06-17 | 2022-09-23 | 昆山德诺瑞尔生物科技有限公司 | Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用 |
| AU2023229967A1 (en) * | 2022-03-11 | 2024-08-08 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| AU2006241099B2 (en) * | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| SG189957A1 (en) | 2010-11-05 | 2013-06-28 | Morphotek Inc | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| SI2731972T1 (en) * | 2011-07-15 | 2018-04-30 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
-
2016
- 2016-04-14 US US15/566,888 patent/US20180125970A1/en not_active Abandoned
- 2016-04-14 AU AU2016248222A patent/AU2016248222A1/en not_active Abandoned
- 2016-04-14 CN CN201680028727.8A patent/CN107624071A/zh active Pending
- 2016-04-14 SG SG11201708546UA patent/SG11201708546UA/en unknown
- 2016-04-14 BR BR112017022320A patent/BR112017022320A2/pt not_active Application Discontinuation
- 2016-04-14 WO PCT/US2016/027497 patent/WO2016168440A1/en not_active Ceased
- 2016-04-14 EP EP16718820.0A patent/EP3283886B1/en active Active
- 2016-04-14 KR KR1020177032864A patent/KR20170137848A/ko not_active Withdrawn
- 2016-04-14 MX MX2017013390A patent/MX2017013390A/es unknown
- 2016-04-14 JP JP2017554475A patent/JP2018516244A/ja active Pending
- 2016-04-14 CA CA2983126A patent/CA2983126A1/en not_active Abandoned
- 2016-04-14 RU RU2017136863A patent/RU2718780C9/ru not_active IP Right Cessation
-
2017
- 2017-10-17 IL IL255079A patent/IL255079A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016248222A1 (en) | 2017-11-09 |
| JP2018516244A (ja) | 2018-06-21 |
| IL255079A0 (en) | 2017-12-31 |
| RU2017136863A (ru) | 2019-05-17 |
| BR112017022320A2 (pt) | 2018-07-24 |
| EP3283886B1 (en) | 2020-01-15 |
| RU2718780C9 (ru) | 2020-07-08 |
| RU2718780C2 (ru) | 2020-04-14 |
| US20180125970A1 (en) | 2018-05-10 |
| RU2017136863A3 (es) | 2019-08-21 |
| SG11201708546UA (en) | 2017-11-29 |
| CA2983126A1 (en) | 2016-10-20 |
| EP3283886A1 (en) | 2018-02-21 |
| CN107624071A (zh) | 2018-01-23 |
| WO2016168440A1 (en) | 2016-10-20 |
| KR20170137848A (ko) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013390A (es) | Método para el tratamiento de cáncer pulmonar. | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| JO3681B1 (ar) | استخدام مجموعات الجين الطافر fgfr في الكشف عن مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط fgfr | |
| MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| EP2209495A4 (en) | TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| MX2018003376A (es) | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. | |
| BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
| ZA201803207B (en) | MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
| BR112015031729A2 (pt) | sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama | |
| MX2017006242A (es) | Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. | |
| MX2018007589A (es) | Ccl20 como indicador de respuesta clinica a antagonistas de il23. | |
| BR112016024143A2 (pt) | tratamento de câncer | |
| CA2967867C (en) | Methods for detection and treatment of colorectal cancer | |
| WO2015181555A8 (en) | Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent | |
| WO2019053116A8 (en) | Method for guidance of fluid therapy based on proadrenomedullin | |
| AR104791A1 (es) | Métodos terapéuticos y diagnósticos para el cáncer | |
| UA104420U (uk) | Спосіб прогнозування зрощення перелому | |
| UA104421U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95662U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95588U (uk) | Спосіб прогнозування зрощення перелому | |
| BR112017012553A2 (pt) | método de tratamento de um paciente que sofre de um câncer, método para o diagnóstico de um câncer, método para o prognóstico de um paciente que sofre de câncer, método para determinar se um paciente com um câncer e método para otimizar a eficácia terapêutica de uma terapia anticâncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: EISAI INC. |